Hongsheng Su

Title: The Innovations of Hongsheng Su

Introduction

Hongsheng Su is a notable inventor based in Kaifeng, China. He has made significant contributions to the field of biotechnology, particularly in the development of blood-clotting factors. His work has implications for improving drug efficacy and patient outcomes in medical treatments.

Latest Patents

Hongsheng Su holds a patent for a highly glycosylated human blood-clotting factor VIII fusion protein, along with its manufacturing method and applications. This innovative fusion protein includes a human factor VIII, a flexible peptide connector, and a rigid unit of a human chorionic gonadotropin β-subunit carboxyl terminal peptide. Additionally, it features a half-life extending portion, preferably selected from a human IgG Fc variant. The fusion protein demonstrates a similar level of biological activity as recombinant factor VIII while extending its in vivo half-life, thereby enhancing pharmacokinetics and drug efficacy.

Career Highlights

Throughout his career, Hongsheng Su has worked with prominent companies in the pharmaceutical industry, including Kaifeng Pharmaceutical (Group) Co., Ltd. and Furen Pharmaceutical Group Co., Ltd. His experience in these organizations has allowed him to apply his innovative ideas in practical settings, contributing to advancements in medical treatments.

Collaborations

Hongsheng Su has collaborated with notable colleagues, including Luyan Zhu and Yuanli Li. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the field of biotechnology.

Conclusion

Hongsheng Su's contributions to the development of blood-clotting factors highlight his role as an influential inventor in the biotechnology sector. His innovative work continues to impact medical treatments and improve patient care.